Akero Therapeutics Inc

NASDAQ:AKRO  
45.46
-0.23 (-0.50%)
6:08:21 PM EDT: $44.00 -1.46 (-3.21%)
Earnings Announcements

Akero Therapeutics Reports Third Quarter 2022 Financial Results

Published: 11/04/2022 11:12 GMT
Akero Therapeutics Inc (AKRO) - Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update.
Remains on Track to Report Results of Cohort D in the First Half of 2023.
Cash and Cash Equivalents for the Period Ended September 30, 2022, Were $374.0 Million.
Akero Therapeutics - Believes Cash, Cash Equivalents and Marketable Securities Will Be Sufficient to Fund Its Current Operating Plan Into 2025.
Qtrly Loss per Share $0.92.
Q3 Earnings per Share View $-0.74 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.77

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.87

More details on our Analysts Page.